Starling Oncology (STLNW) Current Assets (2019 - 2026)

Starling Oncology (STLNW) has reported Current Assets for 8 consecutive years, with $129.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 23.09% year-over-year to $129.0 million; the trailing twelve-month figure through Jun 2026 stood at $129.0 million (up 23.09% YoY), and the FY2025 full-year result was $112.7 million, changed 0.29% from the prior year.
• Current Assets improved to $129.0 million in Q2 2026 per STLNW's latest filing, from $116.9 million in the prior quarter.
• Across five years, Current Assets topped out at $152.7 million in Q3 2023 and bottomed at $104.1 million in Q2 2023.
• Historically, Current Assets has averaged $122.9 million across 5 years, with a median of $116.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Current Assets soared 49926.47% in 2022, then dropped 24.34% in 2025.
• Over 5 years, Current Assets stood at $130.4 million in 2022, then rose by 10.03% to $143.5 million in 2023, then retreated by 21.66% to $112.4 million in 2024, then gained by 0.29% to $112.7 million in 2025, then advanced by 14.41% to $129.0 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $129.0 million, $116.9 million, and $112.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.